Ethan Weiss highlights large triglyceride and remnant cholesterol reductions with olezarsen at 6 months, while ACC posts on the ESSENCE-TIMI 73b CCTA substudy note no difference in noncalcified coronary plaque volume, challenging assumptions about plaque impact.
At 6 months, olezarsen reduced triglycerides by 63.9%, remnant cholesterol by 71.9%, and apolipoprotein B by 16.0% over placebo, with no difference in LDL-C.
In CCTA substudy of Essence-TIMI 73b (RCT of olezarsen vs. placebo in patients with hypertriglyceridemia), no difference in non calcified, coronary plaque volu...
Study does not demonstrate support the hypothesis that ⤵️ in RC and TRL have an outsized cardiovascular
At 6 months, olezarsen reduced triglycerides by 63.9%
remnant cholesterol by 71.9%
with no difference in LDL-C.
It feels quite earth-shattering to me
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare